A carregar...
Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel
Despite impressive initial clinical responses, the majority of lung cancer patients treated with paclitaxel eventually develop resistance to the drug. Pyruvate dehydrogenase kinase-2 (PDK2) is a key regulator of glycolysis and oxidative phosphorylation, and its expression is increased in a variety o...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581057/ https://ncbi.nlm.nih.gov/pubmed/28881758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16991 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|